Montpellier, June 13, 2022 at 8:00 a.m. – MEDESIS PHARMA, a pharmaceutical biotechnology company developing drug candidates based on its proprietary Aonys® technology for administering active ingredients in nano micelles by oral route, announces the first inclusions of patients in the Phase II clinical trial of its NanoLithium program for the treatment of Alzheimer’s disease.
In parallel, Medesis Pharma is carrying out developments for the treatment of severe forms of COVID-19, in clinical Phase II in Brazil, preclinical developments for the administration of small interfering RNAs for the genetic treatment of Huntington’s disease and certain cancers resistant to treatment and is pursuing the development of 3 drug candidates for populations contaminated or irradiated after a civil or military nuclear accident.